



IPMAR

IPSC Platform to Model Alzheimer's Disease Risk

Certificate of analysis

DRICUi054-A

Operators: C Bridge/J Winston/R O'Donoghue

Date: 17/06/2026

Supervisor: H Hall-Roberts

Date: 19/06/2026

Signature:

HCRoberts


Source of cells and reprogramming information

- ADLON40385CA T cells from Cardiff 16/05/23
- Reprogrammed at UOXF AKA IPMAR61
- Reprogrammed on 05/2023 Sally Cowley/
Sarah Ellwood (Oxford)
- Reprogramming system Cytotune v2
- Clone DRICUi054-A = IPMAR61A5
- Banked at P12, 22/10/24, Jincy Winston
(Cardiff)


Viability post-thaw and Morphology according to JMSCFSOP19 passage 13

- Vial cell count immediately post-thaw 1.18×10^6
- Viability immediately post-thaw 92.9%
- Photo at day 2 post-thaw (scale bar = $100\mu\text{m}$):

Day 2 post-thaw, 20% plated to 1w.6wp



Sendai Cytotune 2 clearance: according to Cytotune manual Virus undetectable at passage 10



Product sizes: SeV 181bp; KOS 528bp; SeV-Klf 410bp; SeV-Myc 532bp; Actin 623bp


Sterility:

Mycoplasma test performed by Eurofins Genomics on 24/03/2025, undetectable at passage 14.


Visual inspection of thawed cells cultured without antibiotic/antimycotic for 4 days:
no evidence of bacteria, yeast or fungus.

Flow cytometric analysis according to JMSCFSOP05 passage 12

DRICUi054-A TRA-1-60 98.7%




DRICUi054-A Nanog 99.8%



Illumina GSA SNP analysis according to JMSCFSOP16

- Passage 12
- Identity to parent PBMC confirmed
- Karyotype abnormalities:
 - No gross abnormalities detected vs PBMC

Karyogram ADLON40385CA PBMC



Karyogram DRICUi054-A

